Recruiting studies: Recurrent Transformed Follicular Lymphoma To Diffuse Large B

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05672251 Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antige
Phase 2 · 1 location(s) · University of California, Davis · NCT06854159 Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373 A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcita
Phase 2 · 53 location(s) · Hoffmann-La Roche · NCT06806033 CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Phase 1 · 1 location(s) · Nathan Denlinger · NCT06209619 Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2 · 87 location(s) · SWOG Cancer Research Network · NCT05633615 Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Phase 2 · 1 location(s) · University of Washington · NCT06784726 Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Expo
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT07042438 Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treat
Phase 2 · 1 location(s) · University of California, Davis · NCT06905509 Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Phase 2 · 104 location(s) · SWOG Cancer Research Network · NCT05890352

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.